Axcelon Biopolymers Corporation Files IPO Prospectus, Pioneering Bacterial Nanocellulose from Wound Care to Drug Delivery

Bacterial cellulose, a natural biomaterial intricately woven by microorganisms, stands out with its unique three-dimensional networked nanofiber structure, demonstrating exceptional mechanical strength, superior water-retention properties, and stable suspension capability.

Compared with traditional plant cellulose, bacterial cellulose retains a similar molecular backbone but eliminates redundant components such as lignin, hemicellulose, and pectin, resulting in superior performance: higher crystallinity imparts exceptional structural integrity, enhanced stability ensures reliable performance across diverse environments, and excellent biocompatibility further expands its applications in the biomedical field.

Therefore,Bacterial cellulose is hailed as the “shining pearl of the cellulose world,” leading the new trend in biomaterials.。

As an innovation pioneer in the field of biomaterials, Axcelon Biopolymers Corporation is deeply exploring the infinite potential of this “noble” material. It is understood thatLeveraging its independently developed bacterial nanocellulose (BNC) platform technology, the company has created a series of high-value-added products for wound care, medical devices, tissue engineering, and industrial applications.。

In 2001, Chandra J. Panchal founded Axcelon. Prior to establishing Axcelon, Panchal was also a co-founder of Procyon Biopharma Inc., a publicly listed biotechnology company focused on commercializing innovative therapies in the fields of cancer and HIV. It is understood that Procyon Biopharma Inc. was listed on the Alberta Stock Exchange in 1998 and on the Toronto Stock Exchange in 2000, at which point it was renamed Ambrilia BioPharma Inc.

According to the official website of Ambrilia BioPharma Inc., its product Octreotide is used to treat acromegaly, a rare disease caused by pituitary tumors, as well as certain gastrointestinal tumors; while Goserelin is primarily used to treat hormone-sensitive prostate cancer.

Embarking on a new entrepreneurial venture, Panchal expanded his business into biomaterials, focusing on bacterial nanocellulose (BNC) platform technology. As early as 1991, Japan successfully fabricated artificial blood vessels using bacterial cellulose for the first time, and in 2001, it further developed artificial blood vessels with inner diameters of 1–3 mm. In recent years, bacterial cellulose has become a hot topic in international research on biomedical materials. However, due to high costs, low yields, and a disconnect in technology translation, bacterial cellulose has yet to achieve large-scale industrialization in medical material products.

Following the establishment of Axcelon, Chandra J. Panchal began to introduce a completely new management team.Wankei Wan serves as Chief Technology Officer at AxcelonAccording to the official website, Wankei Wan is not only the Director of the AFMNet Transgenic Spider Silk Research and Biomedical Engineering Graduate Program but also a full-time professor in the Department of Chemical and Biochemical Engineering at Western University. Additionally, Wankei Wan holds patents for dissolving and casting bacterial cellulose, as well as three other patents and patent applications related to bacterial cellulose.

Newly appointed President and Chief Operating Officer Dino Mili is responsible for the development of the Axcelon project., in terms of acquisitions and project financing. Over the past three decades, he has participated in investments totaling more than $450 million. AndSenior Consultant Wankei Wan has over 35 years of experience in process engineering and project execution across the industrial gases, chemical, wastewater and water treatment, pulp and paper, and fermentation industries.Over the past 26 years, he has served as a Senior Development Engineer and Business Development Professional at Praxair Canada, conducting operations in Canada, the United States, and China. He has designed, built, and commissioned processes for gas/liquid mixing, gas dissolution, CO2 pH control, and fermentation for key clients.

Technologically, Axcelon unites the R&D prowess of two distinguished scientists, dedicated to pushing the innovative boundaries of materials engineering. Its areas of exploration range from the novel incorporation of silver nanoparticles into antimicrobial dressings to the development of advanced composite materials integrating polyvinyl acetate (PVA) and poly-HEMA.

According to Patent Star search,Axcelon pioneered the patent layout for “silver nanoparticle-coated bacterial cellulose” in 2007.Silver-coated bacterial cellulose nanofibers are prepared by preparing a suspension of bacterial cellulose fibers, oxidizing the bacterial cellulose fibers, introducing thiol groups onto the polymer backbone, allowing the product to react with silver proteinate, and increasing the particle size of the silver nanoparticles. Silver-coated bacterial cellulose nanofibers possess antibacterial properties.

Axcelon subsequently filed 20 patents. On November 19, 2015, Axcelon announced that it had licensed a patent covering the material composition of “polyvinyl alcohol–bacterial cellulose nanocomposites,” derived from a proprietary cellulose-producing bacterial strain. This novel strain produces cellulose several times faster than conventional strains, potentially lowering the entry barriers for industrial applications of bacterial cellulose across sectors ranging from aerospace, automotive, and construction to textiles, food, and specialty paper.

According to information disclosed by Axcelon, anisotropic polyvinyl alcohol-bacterial cellulose nanocomposites possess ideal properties and hold potential for use as small-diameter vascular grafts in bypass surgeries, such as coronary artery bypass grafting, for which no off-the-shelf grafts are currently available.。

In addition to its patents on polyvinyl alcohol-bacterial cellulose nanocomposites, Axcelon holds patent positions on other composite materials, such as PolyHEMA-BC transparent nanocomposites for optical applications and biocompatible polyamides for imparting biocompatibility to biomedical catheters.

In 2014, Axcelon Biopolymers Corporation announced that its subsidiary, Axcelon Dermacare Inc. (ADI), had completed a $1 million private placement financing, which would be primarily used for the commercialization of ADI’s lead product, Nanoderm™.

According to Chandra Panchal, this is a simple, single-use dressing application,Nanoderm™ provides an effective barrier against infection while maintaining an ideal moist wound environment, allowing for gas exchange and pain relief. Nanoderm™ is suitable for a variety of treatments, including second-degree burns, skin abrasions, and acute and chronic wounds.

To further consolidate its leading position in the field of wound care, Axcelon launched Nanoderm™Ag in 2017. This upgraded product chemically bonds silver with bacterial cellulose, creating a more stable and long-lasting antimicrobial dressing. The introduction of Nanoderm™Ag not only enhances the antimicrobial efficacy of wound care but also extends the dressing change interval, offering patients greater convenience and peace of mind.

Meanwhile, Axcelon has not limited itself to the field of wound care. Leveraging its extensive expertise in bacterial nanocellulose (BNC) and other biomaterials, the company is actively developing a series of innovative medical devices to meet the urgent demands of large-scale markets.From vascular grafts to tympanic membrane replacements, and from contact lenses to vaccine delivery systems, Axcelon is continuously expanding its footprint in the medical device sector with its unique perspective and technological advantages.

In particular, in the field of vaccine delivery systems, Axcelon is developing a system that uses nanocrystalline bacterial cellulose fibers to deliver drugs directly to cells. This innovative technology is expected to revolutionize vaccine delivery by enabling oral vaccines to remain active in the harsh environment of the stomach, thereby significantly reducing treatment costs and improving vaccine efficacy.

Furthermore,Axcelon is also targeting high-value segments in industrial applications, developing a series of high-performance materials based on BNC.. Compared with traditional bacterial cellulose production methods, this bacterial strain demonstrates significantly higher yield, and is expected to enable Axcelon to accelerate its bacterial cellulose production.

In 2017, Axcelon announced the establishment of its demonstration-scale bacterial nanocellulose (BNC) production facility in the St. Facimliicien region of the United Kingdom. This project will leverage Axcelon’s proprietary BNC biology to produce high-value bioproducts for the wound care, medical device, and industrial sectors. Mr. Giles Portman, Mayor of St. Facimliicien, noted that the project will be located in an industrial park and will utilize waste “warm water” energy from a biomass power plant to reduce operating costs.

From the perspective of the domestic market, China’s research and production capabilities in the frontier field of bacterial cellulose, a cutting-edge bio-based material, remain relatively weak. Key participants include well-known enterprises such as Hainan Yeguo Food Co., Ltd., Dinghan Henghai Biotechnology Co., Ltd., and Shandong Naimede Biotechnology Co., Ltd., as well as higher education institutions and research organizations like Qilu University of Technology and the University of Science and Technology of China. In terms of production capacity distribution, Hainan Province has emerged as the primary hub for bacterial cellulose production in China.

For example, Dinghan Henghai Biotechnology is a developer of bacterial cellulose-based medical dressings. The company is dedicated to the research and development of a series of bacterial cellulose medical dressings for wound care applications. It was the first in China to apply the novel bionanomaterial, bacterial cellulose, to the medical field. This product series is primarily used in clinical settings for burns and scalds, plastic and cosmetic surgery, general surgical procedures, and secondary skin ulcers resulting from other diseases, demonstrating broad market prospects both domestically and internationally.

As an emerging and highly promising biomaterial, bacterial cellulose boasts broad market development space and prospects due to its eco-friendly, purely natural, and high value-added characteristics. However, constrained by complex and technically challenging production processes, the current industrial output of bacterial cellulose remains at a relatively low level, with its application areas being comparatively limited. Future applications of bacterial cellulose in fields such as biomedicine, food, papermaking, and environmental protection remain to be further developed.